Agarwal, Devansh http://orcid.org/0000-0001-8342-6119
Dash, Nicholas
Mazo, Kevin W. http://orcid.org/0000-0003-4094-034X
Chopra, Manan http://orcid.org/0000-0001-8928-2275
Avila, Maria P.
Patel, Amit
Wong, Ryan M. http://orcid.org/0000-0001-8055-406X
Jia, Cairang
Do, Hope
Cheng, Jie
Chiang, Colette
Jurlina, Shawna L.
Roshan, Mona http://orcid.org/0000-0003-4068-7700
Perry, Michael W. http://orcid.org/0000-0002-5977-8031
Rho, Jong M.
Broyer, Risa
Lee, Cassidy D.
Weinreb, Robert N. http://orcid.org/0000-0001-9553-3202
Gavrilovici, Cezar http://orcid.org/0000-0003-4286-327X
Oesch, Nicholas W. http://orcid.org/0000-0001-6972-0741
Welsbie, Derek S.
Wahlin, Karl J. http://orcid.org/0000-0002-0494-8304
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (K99/R00EY024648, R01EY031318, R21EY031122, P30EY022589, R01EY031714, R01EY029342)
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
Foundation Fighting Blindness
Research to Prevent Blindness
BrightFocus Foundation
California Institute for Regenerative Medicine (DISC1-08683)
U.S. Department of Health & Human Services | National Institutes of Health (S10OD026929)
Michael Luzich in honor of Norman and Carol Luzich for providing generous funding for this work.
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
Glaucoma Research Foundation
Article History
Received: 22 December 2022
Accepted: 31 August 2023
First Online: 29 September 2023
Competing interests
: K.J.W., D.A., N.D., and R.M.W. have filed a United States provisional patent (63/478416) for work related to RGC reprogramming. J.M.R. is the chief medical officer for Path Therapeutics, Inc., consultant for Danone Nutricia, Cerecin, Eisai, Biocodex, Zogenix and in the speaker’s bureau for Aquestive Pharmaceuticals. The remaining authors declare no competing interests.